Life Tech Therapeutics

Immunomodulating peptide that activates the cytotoxic functions of macrophages to fight cancers or infectious diseases

Fill out the form to download the document

Immunomodulation offers new therapeutic possibilities by re-engaging the immune system against disorders in the body (pathogenic infection, carcinogenesis, etc.).
Macrophage polarisation improves phagocytic capacity as the body's first line of protection.
 

Competitive advantages

  • Specific immunomodulatory action to limit the development of resistance
  • Potential for synergistic action with existing drugs
  • Identification of a membrane receptor and signalling pathway
  • Short-sequence peptide: simple to manufacture and low-cost
     

Applications

  • Treatment of solid cancers
     

Intellectual property

  • Patent

Development stage

Validation of the technology in a real environment
 

Laboratory

RESTORE UT3

Description

Peptide of natural origin:

  • Able to activate the cytotoxic functions of macrophages against pathogens recognised by type C lectin receptors (fungi, yeasts, parasites) and tumour cells
  • Enables the production of pro-inflammatory cytokines
  • Specifically activates macrophages at the tumour site
     
Schéma action des peptides au niveau du site tumoral

Technical specifications

  • No direct microbicidal activity
  • No obvious cytotoxicity (on human erythrocytes and monocytes)
  • In vitro and in vivo efficacy data in a mouse model of Candida albicans
  • In vitro efficacy data in a model of lymphoma and colon and ovarian cancer cells
  • Anti-tumour effect of P17 in a mouse model of acute colorectal carcinosis